The investigation of lipoprotein-related phosfolipase a2 (lp-pla2) v279f mutation in coronary artery disease

Objective: Despite advances in the treatment of cardiovascular diseases, coronary artery disease (CAD) maintains to be the leading cause of death in many nations. The media layer of normal and diseased arteries contains lipoprotein-associated phospholipase A2 (Lp-PLA2), which is mostly made by mast, T lymphocytes, and monocytes. Our research sought to define how the Lp-PLA2 and V279F gene polymorphisms relate to CAD. Materials and Methods: This study included 71 controls and 109 patients. Fasting blood glucose (FBG) and lipid profiles, were measured the enzymatic colorimetric technique. Lp-PLA2 levels were detected with ELISA. The genomic DNAs were isolated from whole blood. Real-time polymerase chain reaction (RT-PCR) with the V279F mutation detection kit was used to identify the Lp-PLA2 V279F mutation. Results: In the CAD compared to the controls, serum Lp-PLA2 levels were higher (p 0.001). While FF (mutant) genotypes and VF (heterozygous) genotypes were absent from both groups, the Lp-PLA2 V279F mutation was discovered as the VV (wild) genotype in both control and CAD. Conclusion: As a result, we determined that the Lp-PLA2 V279F mutation cannot be considered a genetic risk factor for CAD, but that Lp-PLA2 elevation may be an important parameter for CAD.